Urodynamix Technologies Ltd. (TSX VENTURE:URO) ("Urodynamix" or the "Company")
is pleased to announce that it has entered into consulting agreements with each
of Jim Heppell and David Raffa, pursuant to which Heppell and Raffa, through
their respective management companies, will provide all of the management
services necessary for overseeing the business and operations of the Company.
Each of the agreements provides for an annual consulting fee of $60,000, and a
potential bonus based on the EBITDA, if any, produced by the Company.


With the sale of the medical device business now completed, Heppell and Raffa
have aggressively cut back on expenses and are actively engaged in pursuing new
business opportunities for the Company. Announcements in this regard will be
made as these activities progress.


Steps have been commenced to schedule the 2011 Annual General Meeting of the
shareholders of the Company. The Company will provide further particulars when
the meeting and agenda have been finalized.


Forward-looking Statements:

Certain information contained in this press release may be forward-looking and
is subject to unknown risks, which could cause actual results to differ
materially from those set forth or implied herein. Although the Company believes
that the expectations reflected in such forward-looking statements are
reasonable, it can give no assurance that such expectations will prove correct.


Urodynamix Technologies Ltd. (TSXV:URO)
Graphique Historique de l'Action
De Juil 2024 à Août 2024 Plus de graphiques de la Bourse Urodynamix Technologies Ltd.
Urodynamix Technologies Ltd. (TSXV:URO)
Graphique Historique de l'Action
De Août 2023 à Août 2024 Plus de graphiques de la Bourse Urodynamix Technologies Ltd.